Dr NEIL VARGESSON

Senior Lecturer

BSc (Hons)., Ph.D., FHEA

Contact Details

Telephone: +44 (0)1224 437374
Fax: +44 (0)1224 437506
Email: n.vargesson@abdn.ac.uk
Address: School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, Room 5.15.5, University of Aberdeen. Foresterhill. Aberdeen. AB25 2ZD. Scotland.
hCard

For a recent discussion about Thalidomide research and some of the goals we have please see the following article published in 'The Conversation' and the 'Independent':

https://theconversation.com/thalidomide-the-drug-with-a-dark-side-but-an-enigmatic-future-50330

http://www.independent.co.uk/news/science/thalidomide-the-drug-with-a-dark-side-but-an-enigmatic-future-a6772956.html

 

Biography

August 2013  Senior Lecturer, School of Medical Sciences, University of Aberdeen.

August 2007   Lecturer, School of Medical Sciences, University of Aberdeen.

2006 - Fellow of the Higher Education Academy (FHEA)

2005 - CASLAT (Cerificate of Advanced Study in Learning and Teaching), Imperial College

2004 - 2007    Lecturer. NHLI Division, Faculty of Medicine. Imperial College London.

2001 - 2003    Postdoctoral Fellow. Cancer Research UK, London. UK, with Dr Julian Lewis studying zebrafish gut development.

1998 - 2001    Postdoctoral Fellow. Department of Genetics and Development, Columbia University, New York. USA, with Dr Ed Laufer studying TGFbeta signalling in chick limb development (funded by HFPSO Long-Term Fellowship)

1998 - Ph.D (Developmental Biology), University College London (with Profs Lewis Wolpert and Cheryll Tickle)

1994 - B.Sc. (Hons) Human Biology, Kings College London

Research Interests

Research in the lab is focused on determining the mechanisms underlying thalidomide-induced teratogenesis; identifying non-teratogenic forms of thalidomide; how blood vessels are involved in controlling normal and abnormal Limb development; using the chicken embryo to produce a model of Clubfoot to understand how this common birth anomaly comes about; and understanding how birth defects  come about in general.

 

For a recent discussion written for the public about Thalidomide and some of the goals we have please see the following article published in 'The Conversation' and also in the 'Independent':

https://theconversation.com/thalidomide-the-drug-with-a-dark-side-but-an-enigmatic-future-50330

http://www.independent.co.uk/news/science/thalidomide-the-drug-with-a-dark-side-but-an-enigmatic-future-a6772956.html

 

For recent discussions written for the public on other topics related to birth defects please see the following articles:

https://theconversation.com/is-primodos-the-forgotten-thalidomide-50673

https://theconversation.com/proving-that-the-zika-virus-causes-microcephaly-53716

 

Current Research

Thalidomide:
We have demonstrated (Therapontos et al., 2009) how thalidomide can cause limb malformations. The drug was used as a non-addictive, non-barbiturate sedative and was also prescribed to pregnant women suffering from morning-sickness (typically, but not exclusively, between weeks 5-10). Tragically over 10000 children were born with severe birth defects, notably, and commonly, limb malformations.

Using analogs and metabolic byproducts of the drug, we showed that its the antiangiogenic action of the drug that causes limb defects, through preventing blood vessel migration into the developing limb bud. We further showed how the drug exerts its antiangiogenic effect, through preventing endothelial cell proliferation and migration and thus, preventing vessel tube networks from forming. At the time the limb forms (which in humans is around 5-8 weeks) it has a highly changeable vessel pattern - whereas the rest of the body has a stable vascular network. Thalidomide prevents new vessel outgrowth, which then causes an increase in cell death and loss of limb signalling pathways, stopping limb formation.
 

Reference:

Therapontos, C., Erskine, L., Gardner, E. R., Figg, W. D. and Vargesson, N. (2009). Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl. Acad. Sci USA. 106, 8573-8578. DOI:10.1073/pnas.0o01505106.       

 

This work received wide spread media interest, including:

STV: http://news.stv.tv/scotland/95571-scientists-make-thalidomide-breakthrough/

BBC: http://news.bbc.co.uk/1/hi/scotland/north_east/8040535.stm

http://www.clickliverpool.com/news/national-news/124324-thalidomide-victims-welcome-research-breakthough.html

A large number of newspapers, including The Independent, The Daily Mail, The Scotsman, The Press & Journal, and several Radio stations.

The work was also featured in Nature News: 

http://www.nature.com/news/2009/090511/full/news.2009.462.html

 

Making safer Thalidomide alternatives:

We are also interested in identifying thalidomide alternatives that retain the clincial benefits of the drug (successfully used to treat Leprosy and Multiple Myeloma) with lessened or no side-effect (eg: birth defect, peripheral neuropathy). To this end we have compared the effects of Thalidomide with its structural analogs, Lenalidomide and Pomalidomide. We demonstrated that the minor structural changes in Pomalidomide make this compound more anti-inflammatory (and not teratogenic in chicken and zebrafish embryos) at lower concentrations than Thalidomide and Lenalidomide. We have also screened fluorinated thalidomide analogs and demonstrated differences in analog activities. These findings validate making structural changes to Thalidomide to try to find safer alternatives - this work is continuing in our lab.


References:

Mahony, C., Erskine, L., Niven, J., Grieg, NH., Figg, WD., Vargesson, N (2013). Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic invitro. Proc. Natl. Acad. Sci USA. 110, 12703-8. doi: 10.1073/pnas.1307684110

Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, Ambrozak A, Gütschow M, Chau CH, Vargesson N, Figg WD. (2015). Anticancer properties of a novel class of tetrafluorinated thalidomide analogues. Mol Cancer Ther 14:2228-2237. doi: 10.1158/1535-7163.MCT-15-0320.

 

Media Interest

This work was mentioned in The Sunday Times, 4 August 2013.

http://www.thesundaytimes.co.uk/sto/news/uk_news/scotland/article1296248.ece?CMP=OTH-gnws-standard-2013_08_03

And on realradio.co.uk/scotland.

 

Media Interviews/Discussions about our Thalidomide research:

2009 - The Material World (BBC Radio 4) - http://www.bbc.co.uk/programmes/b00k9hlz#synopsis

2010 - The Diane Rehm Show (US Radio) - http://thedianerehmshow.org/shows/2010-09-16/thalidomide-and-fda

2010 - The New York Times - interviewed by Carl Zimmer
http://www.nytimes.com/2010/03/16/science/16limb.html?pagewanted=all&_r=0

2011 - The Naked Scientists (BBC Radio) - http://www.thenakedscientists.com/HTML/content/interviews/interview/1785/ 

2012 - German Public Radio - http://www.dradio.de/dlf/sendungen/hintergrundpolitik/1917460/

http://www.dradio.de/dlf/sendungen/wib/1945008/

2013 - The Today Program (BBC Radio 4) - Thalidomide: Were more babies affected?

2013 - BBV TV News - Thalidomide: Were more babies affected? (Oct 14, 2013)

2013 - BBC News Website - http://www.bbc.co.uk/news/health-24472269

2013 - The Naked Scientists (BBC Radio) -

http://www.thenakedscientists.com/HTML/content/interviews/interview/1000545/

2015 - SHMU Radio - 'Talking Science' (Jan 27, 2015)

 

Some images of my thalidomide work is featured in a Fine Art Exhibition (and subsequent Book) by the renowned artist, Taryn Simon. The Exhibition is entitled: ‘A Living Man Declared Dead and Other Chapters’ and toured the world throughout 2011 and 2012.

 

Media articles about Thalidomide

2015 - The Conversation

https://theconversation.com/thalidomide-the-drug-with-a-dark-side-but-an-enigmatic-future-50330

2015 - The Independent

http://www.independent.co.uk/news/science/thalidomide-the-drug-with-a-dark-side-but-an-enigmatic-future-a6772956.html

Teaching Responsibilities

Degree Programme Co-ordinator - Human Embryology and Developmental Biology

 

Course Co-ordinator - DB3006 Principles of Developmental and Reproductive Biology

External Responsibilities

Editorial Board Member, Reproductive Toxicology


Guest Editor for a Special Issue of Reproductive Toxicology entitled 'Developmental Angiogenesis'

Submissions open until July 2016.
http://www.journals.elsevier.com/reproductive-toxicology/call-for-papers/special-issue-on-developmental-angiogenesis/

 

 

 

 

Positions available for PhD students.

 

I am looking for motivated, self-funded PhD students to join my group. Projects are available to study:

1. Mechanisms of thalidomide teratogenesis

2. Identification of non-teratogenic forms of thalidomide

3. Clubfoot

4. Mechanisms underlying limb proximo-distal outgrowth and pattern

5. Control of vascular patterning in the embryo

Publications 

update | about Staff Pages

back